Cargando…

Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial

INTRODUCTION: Wake up stroke starts in sleep and is a more common form of ischemic stroke. At present, it is still controversial whether wake up stroke can be treated with thrombolytic therapy. Therefore, this study will combine imaging techniques to assess the onset time of wake up stroke patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chun-Yang, Yang, Bin, Li, Dong-Mei, Shi, Qiu-Yan, Li, Hong, Li, Yan-Ling, Wang, Cui-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478595/
https://www.ncbi.nlm.nih.gov/pubmed/32899031
http://dx.doi.org/10.1097/MD.0000000000021958
_version_ 1783580087526883328
author Zhang, Chun-Yang
Yang, Bin
Li, Dong-Mei
Shi, Qiu-Yan
Li, Hong
Li, Yan-Ling
Wang, Cui-Lan
author_facet Zhang, Chun-Yang
Yang, Bin
Li, Dong-Mei
Shi, Qiu-Yan
Li, Hong
Li, Yan-Ling
Wang, Cui-Lan
author_sort Zhang, Chun-Yang
collection PubMed
description INTRODUCTION: Wake up stroke starts in sleep and is a more common form of ischemic stroke. At present, it is still controversial whether wake up stroke can be treated with thrombolytic therapy. Therefore, this study will combine imaging techniques to assess the onset time of wake up stroke patients, and to analyze the imaging characteristics of wake up stroke patients and patients suitable for thrombolytic therapy within the time window. METHODS/DESIGN: This study will be a single-blinded, randomized controlled trial with 2 parallel groups. It will be conducted at North China University of science and technology affiliated hospital. DISCUSSION: There is no consistent conclusion about the pathogenesis of wake up stroke. Wake up stroke is more likely to manifest as small vessel disease. The incidence of wake up stroke patients is relatively high, and the effectiveness and safety of intravenous thrombolysis under the guidance of multimode imaging therapy in wake up stroke need to be further explored by prospective, large-scale studies. TRIAL REGISTRATION: ClinicalTrials.gov, ChiCTR2000034402, Registered on 05 July 2020
format Online
Article
Text
id pubmed-7478595
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74785952020-09-24 Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial Zhang, Chun-Yang Yang, Bin Li, Dong-Mei Shi, Qiu-Yan Li, Hong Li, Yan-Ling Wang, Cui-Lan Medicine (Baltimore) 3700 INTRODUCTION: Wake up stroke starts in sleep and is a more common form of ischemic stroke. At present, it is still controversial whether wake up stroke can be treated with thrombolytic therapy. Therefore, this study will combine imaging techniques to assess the onset time of wake up stroke patients, and to analyze the imaging characteristics of wake up stroke patients and patients suitable for thrombolytic therapy within the time window. METHODS/DESIGN: This study will be a single-blinded, randomized controlled trial with 2 parallel groups. It will be conducted at North China University of science and technology affiliated hospital. DISCUSSION: There is no consistent conclusion about the pathogenesis of wake up stroke. Wake up stroke is more likely to manifest as small vessel disease. The incidence of wake up stroke patients is relatively high, and the effectiveness and safety of intravenous thrombolysis under the guidance of multimode imaging therapy in wake up stroke need to be further explored by prospective, large-scale studies. TRIAL REGISTRATION: ClinicalTrials.gov, ChiCTR2000034402, Registered on 05 July 2020 Lippincott Williams & Wilkins 2020-09-04 /pmc/articles/PMC7478595/ /pubmed/32899031 http://dx.doi.org/10.1097/MD.0000000000021958 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3700
Zhang, Chun-Yang
Yang, Bin
Li, Dong-Mei
Shi, Qiu-Yan
Li, Hong
Li, Yan-Ling
Wang, Cui-Lan
Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title_full Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title_fullStr Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title_full_unstemmed Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title_short Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial
title_sort clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: a randomized controlled trial
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478595/
https://www.ncbi.nlm.nih.gov/pubmed/32899031
http://dx.doi.org/10.1097/MD.0000000000021958
work_keys_str_mv AT zhangchunyang clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT yangbin clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT lidongmei clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT shiqiuyan clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT lihong clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT liyanling clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial
AT wangcuilan clinicalefficacyandimagingevaluationofrecombinanttissueplasminogenactivatorthrombolytictherapyinpatientswithwakeupstrokearandomizedcontrolledtrial